BioLinks: Deep Dive
Member News
Sustained Therapeutics Reports Positive Phase 2 Results for its Long-Acting Non-Opioid Medication for Chronic Pain
Plans to seek regulatory approval to commence a Phase III trial in the US and Canada Vancouver, BC – Sustained Therapeutics Inc., a clinical-stage therapeutics company developing a non-opioid treatment… Read More
Member News
Amplitude Co-leads Oversubscribed $76 million Series B financing for Mediar Therapeutics
Series B Co-led by New Investors Amplitude Ventures and ICG MTX-474 Global Phase 2a study Initiated in Systemic Sclerosis (SSc) MTX-463 Global Phase 2a Study in Idiopathic Pulmonary Fibrosis (IPF)… Read More
Member News
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit
Positive results from Phase 3 HERIZON-GEA-01 results support Ziihera as the HER2-targeted agent-of-choice in HER2+ first-line metastatic GEA and Ziihera plus chemotherapy to replace trastuzumab as the new standard of… Read More
Member News
Johnson & Johnson submits Application to the European Medicines Agency for TECVAYLI®▼ (teclistamab) in Combination with DARZALEX® (daratumumab) Subcutaneous Formulation for Patients With Relapsed/Refractory Multiple Myeloma
Novel immunotherapy combination regimen brings together two complementary therapies to improve outcomes for people living with multiple myeloma as early as second-line1 The application is supported by data from the… Read More